Actively Recruiting
Randomized Study Comparing FWY003 Doses to Placebo in Adults with Geographic Atrophy from Age-related Macular Degeneration
Led by Novartis Pharmaceuticals · Updated on 2026-10-13
272
Participants Needed
59
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying geographic atrophy GA secondary to age-related macular degeneration AMD to understand how different doses of the drug FWY003 affect the condition. This randomized, double-masked, multi-center study aims to characterize the dose-response relationship, as well as assess the efficacy and safety of FWY003 compared to a placebo in adults aged 50 and older with GA due to AMD. Participants are randomly assigned to receive one of three dose levels of FWY003 or a placebo. The study drug or placebo is administered as part of a controlled treatment plan over an 18-month period. The trial includes multiple study groups to compare effects across doses and between the active drug and placebo. During the study, participants will undergo regular assessments including measurements of GA lesion size, visual function tests such as best corrected visual acuity under regular and low luminance, contrast sensitivity, and plasma drug levels. Safety is monitored through adverse event tracking from the first dose through month 19. The main outcome is the change in GA lesion area from baseline to month 18, with treatment effects and safety followed over this period.
CONDITIONS
Brief Title
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here